Isokinetic muscle performance in major depressive disorder: Alterations by antidepressant therapy

被引:2
|
作者
Bilici, M [1 ]
Cakirbay, H
Koroglu, MA
Guler, M
Tosun, M
Aydin, T
Tan, U
机构
[1] BlackSea Tech Univ, Dept Psychiat, TR-61080 Trabzon, Turkey
[2] BlackSea Tech Univ, Dept Phys Therapy & Rehabil, TR-61080 Trabzon, Turkey
[3] Gulhane Mil Med Acad, Dept Sports Med, Ankara, Turkey
关键词
muscle performance; major depression; antidepressants; exercise;
D O I
10.3109/00207450108994218
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The aims of this study were (i) to examine whether patients with major depressive disorder (MDD) differ from healthy control subjects with respect to isokinetic muscle performance (IMP) as measured by a dynamometer; (ii) to investigate the effect of subchronic treatment on the IMP in depressed patients. Thirty-eight patients with MDD, and 41 sex- and age-matched healthy controls participated in this study. The severity of depression and anxiety levels were evaluated by the Hamilton Depression and Anxiety Scales. Quadriceps and hamstring IMPs were determined by using an isokinetic dynamometer before and after subchronic antidepressant treatment. The patients had lower IMP levels than healthy controls. After treatment for three months with selective serotonin reuptake inhibitors, the IMP levels increased significantly. These findings suggest that (i) MDD may be characterized by reduced IMP levels; and (ii) treatment with antidepressants may increase the IMP levels, as a state marker for depression. It was concluded that (i) isokinetic muscle performance may be used as a state marker for monitoring antidepressant drug effects on MDD; (ii) isokinetic exercise increasing IMP may be used in the treatment of depression.
引用
收藏
页码:9 / 23
页数:15
相关论文
共 50 条
  • [21] Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment
    Mellon, S. H.
    Wolkowitz, O. M.
    Schonemann, M. D.
    Epel, E. S.
    Rosser, R.
    Burke, H. B.
    Mahan, L.
    Reus, V. I.
    Stamatiou, D.
    Liew, C-C
    Cole, S. W.
    TRANSLATIONAL PSYCHIATRY, 2016, 6 : e821 - e821
  • [22] Longitudinal Oral and Fecal Microbiome Alterations in Veterans With New Antidepressant Monotherapy for Major Depressive Disorder
    Hoisington, Andrew
    Stearns-Yoder, Kelly A.
    Stamper, Christopher E.
    Simonetti, Joseph A.
    Oslin, David W.
    Brenner, Lisa A.
    BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S162 - S163
  • [23] Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment
    S H Mellon
    O M Wolkowitz
    M D Schonemann
    E S Epel
    R Rosser
    H B Burke
    L Mahan
    V I Reus
    D Stamatiou
    C -C Liew
    S W Cole
    Translational Psychiatry, 2016, 6 : e821 - e821
  • [24] Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
    Dunlop, Boadie W.
    Cole, Steven P.
    Nemeroff, Charles B.
    Mayberg, Helen S.
    Craighead, W. Edward
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 229 : 111 - 119
  • [25] Multimodal antidepressant in Major Depressive Disorder: Use of vortioxetine in depressive outpatients
    Santamaria, O.
    Romero, S. L.
    EUROPEAN PSYCHIATRY, 2018, 48 : S279 - S280
  • [26] Efficacy of Antidepressant Medication in the Treatment of Major Depressive Disorder
    Anderson, Benjamin
    Muller, Andrew
    ARCHIVES OF CLINICAL PSYCHIATRY, 2023, 50 (01) : 123 - 129
  • [27] ANTIDEPRESSANT RESPONSE IN MAJOR DEPRESSIVE DISORDER AND RARE VARIANTS
    Wong, Ma-Li
    Arcos-Burgos, Mauricio
    Licinio, Julio
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1304 - 1304
  • [28] Antidepressant adherence among outpatients with major depressive disorder
    Yassen, Ali Omar
    Mahmud, Nasraw Mustafa
    Bilal, Aya Diyar
    Wahab, Mohd Shahezwan Abd
    PHARMACIA, 2024, 71
  • [29] Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
    Gonda, Xenia
    Sharma, Samata R.
    Tarazi, Frank I.
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (01) : 81 - 89
  • [30] Personalized antidepressant treatment for patients with major depressive disorder
    Chin, Tracy
    Huyghebaert, Trudy
    Svrcek, Clark
    Oluboka, Oloruntoba
    CANADIAN FAMILY PHYSICIAN, 2022, 68 (11) : E301 - E309